Are peptides legal? Where the rules stand in 2026

FDA-approved peptide drugs

Some peptides are FDA-approved prescription drugs. A few examples, with what FDA approved each one for. Each needs a prescription.

• Wegovy (semaglutide): approved for long-term weight management in adults and children 12 and older with obesity (with diet and exercise), and to lower the risk of heart attack and stroke in adults with heart disease and obesity or overweight. FDA label

• Zepbound (tirzepatide): approved for long-term weight management in adults with obesity (with diet and exercise), and moderate to severe obstructive sleep apnea in adults with obesity. FDA label

• Egrifta SV (tesamorelin): approved for reducing extra belly fat in adults with HIV who have lipodystrophy. FDA label

• Vyleesi (bremelanotide): approved for low sexual desire (hypoactive sexual desire disorder) in women before menopause. FDA label

• Imcivree (setmelanotide): approved for weight management in people with certain rare genetic conditions or acquired hypothalamic obesity. FDA label

Compounded peptides and FDA's lists

Federal law lets a state-licensed pharmacy compound (custom-make) a drug for one named patient when it gets a valid prescription. The pharmacy may only use a bulk ingredient that meets an official U.S. Pharmacopeia standard, is part of an FDA-approved drug, or is on FDA's list of ingredients allowed for compounding. 21 U.S. Code section 353a (Pharmacy compounding)

While FDA reviews ingredients that people have asked it to add to that list, it sorts them into groups. Category 1 ingredients may be used while FDA reviews them. Category 2 ingredients raise significant safety risks. Category 3 ingredients lack enough information for FDA to review. FDA says it no longer places ingredients nominated on or after January 7, 2025 into these groups. FDA, updated May 14, 2026

• Category 1

  FDA's list, updated May 14, 2026, puts two peptides in Category 1: GHK-Cu (for uses other than injection) and vasoactive intestinal peptide. FDA took GHK-Cu off on April 22, 2026, then put it back for non-injection uses after one nominator said it meant to withdraw only the injectable form. FDA says it intends to ask its Pharmacy Compounding Advisory Committee about GHK-Cu before the end of February 2027. FDA list, May 14, 2026

• Category 2

  Among peptides, FDA's Category 2 (significant safety risks) lists kisspeptin-10. FDA list, May 14, 2026

• Category 3

  These peptides are in Category 3, meaning they were nominated without enough information for FDA to review them: GHRP-2, GHRP-6, mechano growth factor (MGF), cibinetide (ARA-290) and thymulin acetate. FDA list, May 14, 2026

• Nominated, then withdrawn

  FDA had placed these peptides in Category 2 (significant safety risks). The people who nominated them then withdrew the nominations, so FDA lists them as nominated but withdrawn, and they do not appear in any category on FDA's May 14, 2026 list. (GHK-Cu here means the injectable form.) FDA, updated April 22, 2026

Look up a peptide

Where each peptide named on FDA's lists stands, as of FDA's May 14, 2026 list. Sixteen of these have their own page with sources and what it means for finding a clinician: see the full peptide rules tracker.

The July 2026 advisory committee meeting

• FDA, meeting page updated August 6, 2026

  On July 23 and 24, 2026, FDA's Pharmacy Compounding Advisory Committee met to discuss adding BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon to the list of ingredients pharmacies may use. FDA's meeting page, last updated August 6, 2026, does not post a result. Source

• News report, NCPA, July 31, 2026

  The National Community Pharmacists Association reported on July 31, 2026 that the committee voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax, and voted against emideltide (DSIP). It also reported that the votes are advice, not binding on FDA, that the Secretary of Health and Human Services must still approve any addition, and that pharmacies may not compound these peptides until a final rule is in place. Source

Compounded GLP-1s: semaglutide and tirzepatide

FDA says the shortages of tirzepatide (resolved December 19, 2024) and semaglutide (resolved February 21, 2025) are over. Compounded drugs are not FDA-approved. Now that the shortages are over, pharmacies may not make copies of these drugs unless a prescriber decides and writes down that a change in the compounded version makes a significant difference for that one patient. FDA, updated April 1, 2026

Compare prices for brand-name and compounded versions on the cheapest GLP-1 without insurance.

What "research use only" means

Peptides sold online as "research use only" or "not for human consumption" are not approved for people. FDA has sent warning letters to sellers of these products, saying the labels do not change the fact that the products are being sold as drugs for people, and that they are unapproved new drugs.

• FDA warning letter, March 31, 2026

  Gram Peptides: “Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use.” Source

• FDA warning letter, June 17, 2026

  Wholesale Peptide: “Despite statements on your product labeling marketing your products for, 'RESEARCH USE ONLY' and 'not for human consumption,' evidence obtained from your product labeling, including your website establishes that your products are intended to be drugs for human use.” Source

State rules

Some states add their own rules on top of federal law. We list a state here only when its board or law says so in writing.

• Mississippi: Mississippi's medical, pharmacy and nursing boards say in a joint statement that a health care provider may never compound, give or dispense a peptide that is not FDA-approved or is research-grade, and may not advise, recommend, supply or prescribe one either. Source

Rules for ordering your own lab tests are different; see lab rules by state.

What to do

Talk to a licensed clinician. Ask which peptides the clinic prescribes, whether each one is FDA-approved or compounded, and which state-licensed pharmacy fills it.

Find a licensed clinician for my state

Frequently asked questions

Are peptides legal in the U.S.?

It depends on the peptide and how you get it. FDA-approved peptide drugs are legal with a prescription. A pharmacy may compound a peptide for you with a prescription only if the ingredient meets federal rules. Peptides sold as research use only are not for people.

Is BPC-157 legal?

FDA placed BPC-157 in Category 2 (significant safety risks). The nomination was later withdrawn, so on FDA's May 14, 2026 list it is not in any category, including Category 1. In July 2026 an FDA advisory committee voted to recommend adding it to the list pharmacies may use. NCPA reports that pharmacies may not compound it until a final rule is in place.

What does research use only mean?

It is a label some online sellers put on peptides. FDA has sent warning letters saying that, despite research use only or not for human consumption labels, products marketed for people are drugs for human use and unapproved new drugs.

Is compounded semaglutide legal?

Compounded drugs are not FDA-approved. FDA says the semaglutide shortage ended on February 21, 2025. Since then, pharmacies may make copies only when a prescriber decides and documents that a change makes a significant difference for that one patient.

Do peptide rules differ by state?

Some states add their own rules. For example, Mississippi's medical, pharmacy and nursing boards say a provider may not compound, give, dispense, prescribe or recommend a peptide that is not FDA-approved or is research-grade.

Has FDA made a final decision on BPC-157 and the other peptides from the July 2026 meeting?

Not on the FDA pages we checked on September 26, 2026. FDA's meeting page, last updated August 6, 2026, does not post a decision. Rules can change, so check the linked FDA pages and ask a licensed clinician.

This page explains public rules in plain words. It is not legal or medical advice.